Literature DB >> 23449612

Exhausting T cells in CLL.

Thorsten Zenz1.   

Abstract

In this issue of Blood, Riches and colleagues provide an in-depth characterization of T cells and particularly CD8+ T cells from patients with chronic lymphocytic leukemia (CLL). They demonstrate that CD8+ T cells exhibit defects in proliferation, cytotoxicity, and increased expression of inhibitory receptors and thus exhibit features of T-cell exhaustion.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23449612     DOI： 10.1182/blood-2013-01-475939

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  γδ T cells for immunotherapy.

Authors:  Meixiao Long
Journal:  Blood       Date:  2018-11-22       Impact factor: 22.113

Review 3.  Overcoming T cell exhaustion in infection and cancer.

Authors:  Kristen E Pauken; E John Wherry
Journal:  Trends Immunol       Date:  2015-03-18       Impact factor: 16.687

Review 4.  CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.

Authors:  Zeljko Todorovic; Dusan Todorovic; Vladimir Markovic; Nevena Ladjevac; Natasa Zdravkovic; Predrag Djurdjevic; Nebojsa Arsenijevic; Marija Milovanovic; Aleksandar Arsenijevic; Jelena Milovanovic
Journal:  Curr Oncol       Date:  2022-05-18       Impact factor: 3.109

5.  RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.

Authors:  Elisabeth Salzer; Deniz Cagdas; Miroslav Hons; Emily M Mace; Wojciech Garncarz; Özlem Yüce Petronczki; René Platzer; Laurène Pfajfer; Ivan Bilic; Sol A Ban; Katharina L Willmann; Malini Mukherjee; Verena Supper; Hsiang Ting Hsu; Pinaki P Banerjee; Papiya Sinha; Fabienne McClanahan; Gerhard J Zlabinger; Winfried F Pickl; John G Gribben; Hannes Stockinger; Keiryn L Bennett; Johannes B Huppa; Loïc Dupré; Özden Sanal; Ulrich Jäger; Michael Sixt; Ilhan Tezcan; Jordan S Orange; Kaan Boztug
Journal:  Nat Immunol       Date:  2016-10-24       Impact factor: 25.606

Review 6.  T cell exhaustion: from pathophysiological basics to tumor immunotherapy.

Authors:  Kemal Catakovic; Eckhard Klieser; Daniel Neureiter; Roland Geisberger
Journal:  Cell Commun Signal       Date:  2017-01-05       Impact factor: 5.712

Review 7.  Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

Authors:  Thaiz Rivera Vargas; Lionel Apetoh
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

Review 8.  T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.

Authors:  Elisavet Vlachonikola; Kostas Stamatopoulos; Anastasia Chatzidimitriou
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

Review 9.  Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia.

Authors:  Rodolfo Patussi Correia; Flávia Amoroso Matos E Silva; Nydia Strachman Bacal; Paulo Vidal Campregher; Nelson Hamerschlak; Gustavo P Amarante-Mendes
Journal:  Rev Bras Hematol Hemoter       Date:  2014

10.  Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL.

Authors:  Justyna A Wierzbinska; Reka Toth; Naveed Ishaque; Karsten Rippe; Jan-Philipp Mallm; Lara C Klett; Daniel Mertens; Thorsten Zenz; Thomas Hielscher; Marc Seifert; Ralf Küppers; Yassen Assenov; Pavlo Lutsik; Stephan Stilgenbauer; Philipp M Roessner; Martina Seiffert; John Byrd; Christopher C Oakes; Christoph Plass; Daniel B Lipka
Journal:  Genome Med       Date:  2020-03-18       Impact factor: 11.117
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.